medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2023, Number 11

<< Back Next >>

Ginecol Obstet Mex 2023; 91 (11)

Inflammatory bowel disease in pregnancy: peculiarities and treatment. Review

Lozano VM, Durán CI, Gómez OC, Carmona DE

Language: Spanish
References: 30
Page: 814-822
PDF size: 221.69 Kb.


ABSTRACT

Background: The prevalence of inflammatory bowel disease is estimated to be 0.7% in western countries. Its association with pregnancy is constantly being studied and updated. This disease is associated with several obstetric conditions: prematurity or increased teratogenicity. Medical care and treatment during pregnancy is a challenge.
Objective: To update the knowledge on how pregnancy modifies the course of the disease and how the disease modifies the course of the disease, to mention the safety of treatments for pregnant women and the current obstetric consensus.
Method: Literature search in two databases (PubMed and Embase) with the following search criteria (MeSH): "inflammatory bowel disease" and "pregnancy" of articles published between 2015 and December 2022, written in all languages: meta-analyses, clinical trials, systematic reviews, narratives, prospective and retrospective studies.
Results: 345 records were identified and, after elimination of duplicates and other causes, 30 articles were selected for relevance and novelty.
Conclusion: The pregnant patient with inflammatory bowel disease should be considered high risk and require close follow-up. Pregnancy planning is essential to optimise disease activity and minimise complications. Although most drugs used to treat inflammatory bowel disease.


REFERENCES

  1. Coward S, Clement F, Benchimol EI, et al. Past and futureburden of inflammatory bowel diseases based on modelingof population-based data. Gastroenterology 2019; 156 (5):1345-53.e4. doi:10.1053/J.GASTRO.2019.01.002

  2. Chouraki V, Savoye G, Dauchet L, et al. The changing patternof Crohn’s disease incidence in northern France: acontinuing increase in the 10- to 19-year-old age bracket(1988-2007). Aliment Pharmacol Ther 2011; 33 (10): 1133-42. doi:10.1111/J.1365-2036.2011.04628.X

  3. Cornish J, Tan E, Teare J, et al. A meta-analysis on theinfluence of inflammatory bowel disease on pregnancy.Gut 2007; 56 (6): 830-37. doi:10.1136/GUT.2006.108324

  4. Carbery I, Ghorayeb J, Madill A, Selinger CP. Pregnancyand inflammatory bowel disease: Do we provide enoughpatient education? A British study of 1324 women. WorldJ Gastroenterol 2016; 22 (36): 8219. doi:10.3748/WJG.V22.I36.8219

  5. van der Woude CJ, Ardizzone S, Bengtson MB, et al. TheSecond European Evidenced-Based Consensus on Reproductionand Pregnancy in Inflammatory Bowel Disease. J Crohn’sColitis 2015; 9 (2): 107-24. doi:10.1093/ECCO-JCC/JJU006

  6. Hosseini-Carroll P, Mutyala M, Seth A, et al. Pregnancy andinflammatory bowel diseases: Current perspectives, risksand patient management. World J Gastrointest PharmacolTher 2015; 6 (4): 156. doi:10.4292/WJGPT.V6.I4.156

  7. Kim MA, Kim YH, Chun J, et al. The influence of diseaseactivity on pregnancy outcomes in women with inflammatorybowel disease: a systematic review and meta-analysis.J Crohns Colitis 2021; 15 (5): 719-32. doi:10.1093/ECCOJCC/JJAA225

  8. McConnell RA, Mahadevan U. Pregnancy and the patientwith inflammatory bowel disease: fertility, treatment,delivery, and complications. Gastroenterol Clin North Am2016; 45 (2): 285-301. doi:10.1016/J.GTC.2016.02.006

  9. Costa RV, Simões C, Correia L, Pinto L. Inflammatorybowel disease and pregnancy: is it a marker for adverseoutcomes? Rev Bras Ginecol E Obstet 2022; 44 (10): 915.doi:10.1055/S-0042-1756149

  10. Hoekstra J, Van Roon AHC, Bekkering FC, Van Tilburg AJP,West RL. Decision making and outcome of pregnanciesin female patients with inflammatory bowel disease:findings from a community-based practice. Eur J GastroenterolHepatol 2018; 30 (7): 704-708. doi:10.1097/MEG.0000000000001117

  11. Giessen J van der, Huang VW, Woude CJ van der, Fuhler GM.Modulatory effects of pregnancy on inflammatory boweldisease. Clin Transl Gastroenterol 2019; 10 (3): e00009.doi:10.14309/CTG.0000000000000009

  12. Pedersen N, Bortoli A, Duricova D, et al. The course ofinflammatory bowel disease during pregnancy and postpartum:a prospective European ECCO-EpiCom Study of209 pregnant women. Aliment Pharmacol Ther 2013; 38(5): 501-12. doi:10.1111/APT.12412

  13. Malhi G, Tandon P, Perlmutter JW, Nguyen G, Huang V.Risk Factors for postpartum disease activity in womenwith inflammatory bowel disease: a systematic reviewand meta-analysis. Inflamm Bowel Dis 2022; 28 (7).doi:10.1093/IBD/IZAB206

  14. Watanabe C, Nagahori M, Fujii T, et al. Non-adherence tomedications in pregnant ulcerative colitis patients contributesto disease flares and adverse pregnancy outcomes.Dig Dis Sci 2021; 66 (2): 577-86. doi:10.1007/S10620-020-06221-6/FIGURES/4

  15. Choden T, Mandaliya R, Charabaty A, Mattar MC. Monitoringinflammatory bowel disease during pregnancy: Currentliterature and future challenges. World J GastrointestPharmacol Ther 2018; 9 (1):1. doi:10.4292/WJGPT.V9.I1.1

  16. Voogd F De, Joshi H, Wassenaer E Van, Bots S, D’HaensG, Gecse K. Intestinal ultrasound to evaluate treatmentresponse during pregnancy in patients with inflammatorybowel disease. Inflamm Bowel Dis 2022; 28 (7): 1045.doi:10.1093/IBD/IZAB216

  17. Killeen S, Gunn J, Hartley J. Surgical management of complicatedand medically refractory inflammatory boweldisease during pregnancy. Color Dis 2017; 19 (2): 123-38.doi:10.1111/CODI.13413

  18. Nuñez F. P, Quera R, Sepúlveda E, et al. Pregnancy in inflammatorybowel disease: experience of a chilean cohort.Gastroenterol Hepatol 2021; 44 (4): 277-85. doi:10.1016/J.GASTROHEP.2020.08.005

  19. Tsuda S, Sameshima A, Sekine M, et al. Pre-conceptionstatus, obstetric outcome and use of medications duringpregnancy of systemic lupus erythematosus (SLE), rheumatoidarthritis (RA) and inflammatory bowel disease (IBD) inJapan: Multi-center retrospective descriptive study. ModRheumatol 2020; 30 (5): 852-61. doi:10.1080/14397595.

  20. 2019.166159220. O’Toole A, Nwanne O, Tomlinson T. Inflammatory bowel diseaseincreases risk of adverse pregnancy outcomes: a metaanalysis.Dig Dis Sci 2015; 60 (9): 2750-61. doi:10.1007/S10620-015-3677-X/FIGURES/8

  21. Lee S, Crowe M, Seow CH, et al. The impact of surgicaltherapies for inflammatory bowel disease on femalefertility. Cochrane Database Syst Rev 2019; 2019 (7).doi:10.1002/14651858.CD012711.PUB2/MEDIA/CDSR/CD012711/IMAGE_N/NCD012711-CMP-002-01.PNG

  22. Foulon A, Dupas JL, Sabbagh C, et al. Defining the MostAppropriate Delivery Mode in Women with InflammatoryBowel Disease: A Systematic Review. Inflamm Bowel Dis2017; 23 (5): 712-20. doi:10.1097/MIB.0000000000001112

  23. Ananthakrishnan AN, Cheng A, Cagan A, et al. Mode ofchild-birth and long-term outcomes in women with inflammatorybowel diseases. Dig Dis Sci 2015; 60 (2): 471.doi:10.1007/S10620-014-3353-6

  24. Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M.Pregnancy outcomes in women with inflammatorybowel disease following exposure to thiopurines and antitumornecrosis factor drugs: A systematic review withmeta-analysis. Hum Exp Toxicol 2015; 34 (5): 445-59.doi:10.1177/0960327114550882

  25. Mahadevan U, Long MD, Kane S V., et al. Pregnancyand neonatal outcomes after fetal exposure to biologicsand thiopurines among women with inflammatorybowel disease. Gastroenterology 2021; 160 (4): 1131-39.doi:10.1053/J.GASTRO.2020.11.038

  26. Bortlik M, Machkova N, Duricova D, et al. Pregnancy andnewborn outcome of mothers with inflammatory boweldiseases exposed to anti-TNF-α therapy during pregnancy:three-center study. Scand J Gastroenterol 2013; 48 (8):951-958. doi:10.3109/00365521.2013.812141

  27. Nielsen OH, Gubatan JM, Juhl CB, Streett SE, MaxwellC. Biologics for inflammatory bowel disease and theirsafety in pregnancy: a systematic review and metaanalysis.Clin Gastroenterol Hepatol 2022; 20 (1): 74-87.e3. doi:10.1016/J.CGH.2020.09.021

  28. Gubatan J, Nielsen OH, Levitte S, et al. Biologics duringpregnancy in women with inflammatory bowel diseaseand risk of infantile infections: a systematic review andmeta-analysis. Am J Gastroenterol 2021; 116 (2): 243-53.doi:10.14309/AJG.0000000000000910

  29. Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumabtherapy for Crohn’s disease during pregnancy: a case reportand review of the literature. J Clin Pharm Ther 2017; 42(2): 234-236. doi:10.1111/JCPT.12492

  30. Immune Modulating Therapies in Pregnancy and Lactation| ACOG. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/04/immune-modulating-therapies-in-pregnancy-and-lactation




2020     |     www.medigraphic.com